Perinatal EvidenceCompass
Prepopulated workbenchMED-064

Mood stabilizers/antiseizure — other

Topiramate

Antiseizure medication with off-label psychiatric use; established bipolar efficacy must not be assumed

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Topiramate
Entity type
single-ingredient drug
Active component(s)
Topiramate
Formulation / route / interval
Oral; formulation varies
Attachment entry
Topiramate
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Also: alcohol/cannabis/stimulant use-disorder research and metabolic mitigation
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

5 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

B-017Provisional public source

Topiramate monotherapy is associated with an increased oral-cleft risk.

Public-source certainty descriptor
moderate-to-high—consistent registry evidence
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
first trimester
Comparator
no topiramate/lower-risk ASM
Effect or numbers carried forward

Oral-cleft prevalence approximately 1.4% in the guideline synthesis

Limitations

Dose, indication, and co-medication vary; prevalence is not an adjusted causal effect.

Sources, citation controls, and verification state
PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
B-018Provisional public source

Topiramate is associated with fetal growth restriction/small-for-gestational-age birth.

Public-source certainty descriptor
moderate—observational registry evidence
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy
Comparator
women with epilepsy taking no antiseizure medicine
Effect or numbers carried forward

MHRA communicates about 18 SGA infants per 100 exposed versus 5 per 100 women with epilepsy taking no ASM

Limitations

Regulatory summary; confounding by epilepsy, dose, smoking, and co-medications.

Sources, citation controls, and verification state
PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
B-019Provisional public source

Current UK measures contraindicate topiramate in pregnancy for migraine prevention and restrict epilepsy use to cases with no suitable alternative.

Public-source certainty descriptor
current regulator requirement
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
preconception and pregnancy
Comparator
alternative therapy
Effect or numbers carried forward

Pregnancy-prevention programme with pregnancy testing and highly effective contraception for women of childbearing potential

Limitations

UK-specific; local requirements must be checked elsewhere.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
B-031Provisional public source

Once pregnancy is established, replacing an effective antiseizure medicine requires caution because seizure recurrence can harm the pregnant patient and fetus.

Public-source certainty descriptor
guideline recommendation
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
after conception
Comparator
continuing effective therapy
Effect or numbers carried forward

No single effect estimate; AAN/AES/SMFM caution

Limitations

Decision varies by seizure syndrome, prior control, dose, and drug-specific fetal risk.

Sources, citation controls, and verification state
PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
B-065Provisional public source

Breastfed infants in the MONEAD cohort generally had substantially lower antiseizure-medicine concentrations than their mothers.

Public-source certainty descriptor
moderate—prospective mother-infant cohort for studied agents
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
early lactation
Comparator
maternal serum
Effect or numbers carried forward

Infant concentrations substantially lower than maternal concentrations across studied ASMs

Limitations

Does not cover every ASM equally, rare adverse effects, premature/ill infants, or long-term outcomes.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending